A practical reference on tetrapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-12. Anything still debated is marked as such rather than presented as settled.
Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.
Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Free acid form of the tetrapeptide |
| Molecular mass | About 390.35 Da | Calculated monoisotopic value |
| Appearance | White to off-white powder | Typical lyophilized presentation |
| Solubility | Soluble in water | Also dissolves in buffered saline |
| Storage temperature | Minus 20 degrees Celsius | Dry, dark conditions; avoid repeated thawing |
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
==== Amidation ==== HA can be conjugated with polymers and probes at the carboxyl group using an amidation reaction involving 1-ethyl-3-[3-(dimethylamino)-propyl]-carbodiimide (EDC) and N-Hydroxysuccinimide (NHS). This reaction occurs in water and is used to form more hydrolysis-resistant, non-rearrangeable intermediates that prevent the formation of the irreversible N-acyl urea byproduct, preventing amide bond formation. The amide group in this reaction can also be modified to contain a thiol group, which allows thiols to be covalently linked to HA. Thiol modification can improve many HA properties such as biocompatibility, permeation, and sustained release of a drug. This is because in the presence of biological components, thiols display a great amount of chemo-selectivity and ability to cross-link.
=== Pharmacokinetics === Following oral administration, sarcosine is absorbed from the gastrointestinal tract. It is metabolised to glycine primarily by SARDH in the mitochondrial matrix and to a lesser extent by PIPOX in peroxisomes.
A less common form of cement is non-hydraulic cement, such as slaked lime (calcium oxide mixed with water), which hardens by carbonation in contact with carbon dioxide, which is present in the air (~ 412 vol. ppm ≃ 0.04 vol. %). First calcium oxide (lime) is produced from calcium carbonate (limestone or chalk) by calcination at temperatures above 825 °C (1,517 °F) for about 10 hours at atmospheric pressure:
Sources: en.wikipedia.org
=== 1994–1999: The Double Trio, Vrooom, Thrak and the ProjeKcts === In the summer of 1991, Belew met with Fripp in England to express an interest in reviving King Crimson. That year saw the release of the retrospective box set Frame by Frame: The Essential King Crimson. A follow-up box set, The Great Deceiver, appeared the following year as the first release on Fripp's newly-established record label Discipline Global Mobile (DGM), formed with producer David Singleton. Subsequently, DGM would be the primary home for Fripp's work, with larger album releases distributed to bigger record companies (initially Virgin Records), and smaller releases handled by DGM. This afforded Fripp and his associates greater creative freedom and more control over all aspects of their work.
A growing number of cases seek to enforce liability on gas, oil and coal polluters. In Friends of the Earth v Royal Dutch Shell plc, the Hague District Court held that Shell was bound by the tort provisions of the Dutch Civil Code, Book 6, section 162(2), interpreted in light of the Paris Agreement 2015 article 2(1) and ECHR articles 2 and 8 (rights to life and home), to immediately start cutting all of its emissions by 45% by 2030, whether generated directly by its corporate group (scope 1), indirectly from its purchases (scope 2), or indirectly from its value chain or the purchase and use of its products (scope 3). It emphasised the 'serious and irreversible consequences of dangerous climate change in the Netherlands... pose a threat to the human rights of Dutch residents'. After this loss, Shell dropped "Royal Dutch" from its name, and moved its headquarters to London. In Lliuya v RWE AG Mr Lliuya, who lives in Huaraz, Peru has claimed that RWE AG should pay 0.47% of the costs of flood defences against a melting mountain glacier that increases the size of Lake Palcacocha, because RWE is responsible for 0.47% of historic global greenhouse gas emissions. The Higher Regional Court of Essen gave leave to appeal on whether there is causation of damage, and in 2022 visited the lake. There has also been heightened responsibility on member state governments.
In his victory speech, Lula adopted a moderate tone, saying he wants to "pacify the country". The new government will face a very conservative Congress, with many former ministers and people close to the Bolsonarism. On 1 November 2022, Vice President-elect Geraldo Alckmin was appointed as coordinator of the government-elect transition team. On 3 November, Alckmin and the Chief of Staff of the Presidency, Ciro Nogueira, had a meeting to being the government transition. Lula also met with political leaderships, aiming to adjust the federal budget in 2022, to enable the objectives of the future government.
Sources: en.wikipedia.org
Epitalon is a synthetic tetrapeptide built from four amino acids: alanine, glutamate, aspartate, and glycine. It is not extracted from a natural source but made in the laboratory by chemical synthesis. Its short length makes it relatively straightforward to produce at high purity.
No naturally occurring free form of the peptide has been described. The four-amino-acid sequence can appear as a fragment within larger proteins, but that is not the same as the intact compound being present as a circulating molecule. Materials used in research are synthetic.
Purity is usually checked by reverse-phase high-performance liquid chromatography, which separates the target peptide from related impurities. Mass spectrometry is commonly used alongside it to confirm molecular mass. Some suppliers also provide amino acid analysis for additional sequence confirmation.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.